{
  "ticker": "ZNTL",
  "company_name": "Zentalis Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05682170",
      "title": "Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Acute Myeloid Leukemia (AML)",
      "start_date": "2022-12-01",
      "completion_date": "2024-07-26",
      "enrollment": 0,
      "sponsor": "K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05199337",
      "title": "Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Amyloidosis, AL Amyloidosis",
      "start_date": "2021-11-30",
      "completion_date": "2024-02-14",
      "enrollment": 0,
      "sponsor": "K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04833582",
      "title": "A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma",
      "status": "UNKNOWN",
      "phase": "PHASE1, PHASE2",
      "condition": "Osteosarcoma",
      "start_date": "2021-08-01",
      "completion_date": "2023-12-30",
      "enrollment": 0,
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT05128825",
      "title": "A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "start_date": "2022-02-17",
      "completion_date": "2027-06-30",
      "enrollment": 0,
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT04158336",
      "title": "A Study of ZN-c3 in Participants With Solid Tumors",
      "status": "UNKNOWN",
      "phase": "PHASE1",
      "condition": "Solid Tumor",
      "start_date": "2019-11-01",
      "completion_date": "2023-08",
      "enrollment": 0,
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT05743036",
      "title": "ZN-c3 in Adult Participants With Metastatic Colorectal Cancer",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Metastatic Colorectal Cancer",
      "start_date": "2023-02-27",
      "completion_date": "2025-07-09",
      "enrollment": 0,
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT04814108",
      "title": "A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Uterine Serous Carcinoma",
      "start_date": "2021-07-28",
      "completion_date": "2025-05-31",
      "enrollment": 0,
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc"
    },
    {
      "nct_id": "NCT04854174",
      "title": "A Food Effect Study of ZN-d5 in Healthy Female Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2021-06-13",
      "completion_date": "2021-07-05",
      "enrollment": 0,
      "sponsor": "K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05431582",
      "title": "Phase I Study of ZN-c3 and Bevacizumab \u00b1 Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "Tumors, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer",
      "start_date": "2022-12-14",
      "completion_date": "2022-12-14",
      "enrollment": 0,
      "sponsor": "M.D. Anderson Cancer Center"
    },
    {
      "nct_id": "NCT04516447",
      "title": "A Study of ZN-c3 in Patients With Ovarian Cancer",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer",
      "start_date": "2020-10-26",
      "completion_date": "2027-02-28",
      "enrollment": 0,
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc"
    }
  ],
  "summary": {
    "total_trials": 14,
    "by_phase": {
      "PHASE1, PHASE2": 5,
      "PHASE2": 3,
      "PHASE1": 6
    },
    "by_status": {
      "TERMINATED": 2,
      "COMPLETED": 3,
      "UNKNOWN": 2,
      "RECRUITING": 4,
      "WITHDRAWN": 1,
      "ACTIVE_NOT_RECRUITING": 2
    },
    "active_trials": 6,
    "completed_trials": 3,
    "conditions": [
      "Acute Myeloid Leukemia (AML)",
      "Acute Myeloid Leukemia, Non Hodgkin Lymphoma",
      "Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma",
      "Amyloidosis, AL Amyloidosis",
      "Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer",
      "Healthy Volunteers",
      "High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "Metastatic Colorectal Cancer",
      "Osteosarcoma",
      "Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer",
      "Solid Tumor",
      "Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer",
      "Tumors, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer",
      "Uterine Serous Carcinoma"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T13:12:04.666132",
    "search_query": "Zentalis Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Zentalis+Pharmaceuticals,+Inc."
  }
}